Vatalanib
- Generic Name
- Vatalanib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C20H15ClN4
- CAS Number
- 212141-54-3
- Unique Ingredient Identifier
- 5DX9U76296
- Background
Vatalanib (PTK787/ZK-222584) is a new oral antiangiogenic molecule that inhibits all known vascular endothelial growth factor receptors. Vatalanib is under investigation for the treatment of solid tumors.
- Indication
Used in combination with first- and second-line chemotherapy for the treatment of metastatic colorectal cancer and non-small cell lung cancer (NSCLC).
- Associated Conditions
- -
- Associated Therapies
- -
Temozolomide and Radiation Therapy With or Without Vatalanib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
- Conditions
- First Posted Date
- 2005-08-10
- Last Posted Date
- 2012-09-24
- Target Recruit Count
- 20
- Registration Number
- NCT00128700
- Locations
- ๐ณ๐ฑ
Daniel Den Hoed Cancer Center at Erasmus Medical Center, Rotterdam, Netherlands
๐ฉ๐ชKlinikum der Universitaet Regensburg, Regensburg, Germany
๐ง๐ชU.Z. Gasthuisberg, Leuven, Belgium
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
- Conditions
- Interventions
- First Posted Date
- 2003-11-06
- Last Posted Date
- 2016-08-01
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 155
- Registration Number
- NCT00072475
- Locations
- ๐บ๐ธ
Elkhart General Hospital, Elkhart, Indiana, United States
๐บ๐ธMichael and Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital, Fort Lauderdale, Florida, United States
๐บ๐ธGalesburg Clinic, PC, Galesburg, Illinois, United States
Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.
- Conditions
- Interventions
- First Posted Date
- 2003-03-14
- Last Posted Date
- 2020-02-10
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1168
- Registration Number
- NCT00056459
- Locations
- ๐บ๐ธ
Center for Oncology Research & Treatment, PA, Dallas, Texas, United States
๐บ๐ธUSC/Norris Comprehensive Cancer Care Center, Los Angeles, California, United States
๐บ๐ธPeachtree Hematology and Oncology, Atlanta, Georgia, United States
Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-03-14
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 855
- Registration Number
- NCT00056446
- Locations
- ๐บ๐ธ
UCLA School of Medicine, Los Angeles, California, United States
๐บ๐ธOwensboro Medical Health System, Owensboro, Kentucky, United States
๐บ๐ธColumbus CCOP, Columbus, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.